Key clinical point: The efficacy of fremanezumab for preventive treatment of difficult-to-treat migraine remains unaffected by age or sex.
Main finding: At week 12, quarterly and monthly fremanezumab reduced the monthly average of migraine days irrespective of age (18-45 years: quarterly, −4.1 days; monthly, −4.7 days; placebo, −0.9 days; >45 years: quarterly, −3.6 days; monthly, −3.7 days; placebo, −0.3 days; both P < .001) and sex (men: quarterly, −4.1 days; monthly, −4.6 days; placebo, −0.3 days; women: quarterly, −3.6 days; monthly, −3.9 days; placebo, −0.6 days; both P < .001).
Study details: This post hoc analysis of the phase 3b FOCUS trial included 837 adult patients with chronic/episodic migraine and an inadequate response to multiple alternative therapies, who were randomly assigned to quarterly fremanezumab, monthly fremanezumab, or placebo over 12 weeks.
Disclosures: The study was sponsored by Teva Branded Pharmaceutical Products R&D, Inc., PA. Some of the authors, including the lead author, received research funds or consultancy/speaker fees from various sources including Teva, which the rest were employees/stock owners of.
Source: MaassenVanDenBrink A et al. J Headache Pain. 2021;22:152 (Dec 18). Doi: 10.1186/s10194-021-01336-1.